Do Allergy Shots Last Forever? What the Evidence Shows About Permanence

Allergy shots do not last forever for most patients, but they often provide 3-12+ years of benefit after completing treatment. The persistence of benefit varies by allergen: venom immunotherapy is closest to permanent, with relapse rates below 10% even 10-20 years after stopping (Golden et al., JACI 2017). Grass pollen SCIT shows documented benefit at 3-7 years post-treatment in the Durham landmark studies (NEJM 1999, JACI 2012). Eng et al. (Allergy 2006) followed grass SCIT patients for 12 years post-treatment and found sustained benefit in most subjects. The honest framing: 'long-lasting for many years' is accurate; 'permanent' overstates the evidence for most inhalant allergens.

Patients most likely to have the longest-lasting benefit share several characteristics identified in the literature. Longer treatment duration (5 years vs. 3 years) is associated with better post-treatment durability in retrospective analyses (Naclerio et al., JACI 1997). Younger age at treatment initiation predicts more durable benefit — children treated in the PAT study maintained protection for 7-10 years post-treatment (Jacobsen et al., Allergy 2007). Monosensitization (single allergen trigger) is associated with significantly better durability than polysensitization at 2-year post-treatment follow-up (Yuan et al., Otolaryngol Head Neck Surg 2024). Complete protocol adherence — never missing enough shots to require significant dose reduction — also predicts better durability. For venom allergy, everyone who completes treatment achieves near-permanent protection.

Allergy shot relapse is not an abrupt return to your worst pre-treatment allergy symptoms — it is usually a gradual attenuation of benefit over 1-5 years after stopping treatment. Most relapsers experience a partial return of symptoms: the allergy season is worse than the best treatment year but often not as severe as it was before ever starting shots. IgG4 blocking antibodies decline with a half-life of approximately 21 days but remain above baseline for 2-3 years; regulatory T-cell populations persist even longer. The immunological waning underlying relapse therefore takes time to translate into clinical symptoms. Some patients notice increased antihistamine use before noticing any clear symptom scores worsening — tracking medication use is often the earliest clinical relapse signal.

Yes — retreatment after relapse is generally effective and is typically faster than the original course. The AAAAI/ACAAI Practice Parameter notes that retreatment requires a shorter build-up phase because residual immune memory from the first course means the immune system responds more quickly. Patients retreating after relapse are not starting from immunological scratch — Treg populations and IgG4-producing regulatory B cells established during the original course provide a memory foundation that accelerates re-establishment of tolerance. There is no documented contraindication to SCIT retreatment in otherwise healthy patients. Allergists will reassess the allergen profile and current sensitization status before beginning a second course to ensure the extract mix matches current clinical triggers.

Available evidence suggests that completing 5 years of maintenance provides marginally better post-treatment durability than stopping at 3 years, though high-quality prospective head-to-head data are limited. A retrospective analysis (Naclerio et al., JACI 1997) suggested 5-year courses produced lower relapse rates. The AAAAI/ACAAI Practice Parameter recommends 3-5 years as the optimal window, with the 3-year mark representing the minimum for sustained post-treatment benefit. Patients who have severe initial disease, who relapsed after a previous course, or who have occupational allergen exposure are often recommended to extend to 5 years. The EAACI guideline explicitly states that 2-year courses are insufficient for post-treatment durability, reinforcing the 3-year minimum threshold.

Multiple studies suggest SCIT reduces the development of new allergen sensitivities, though randomized trial evidence is not fully conclusive. Des Roches et al. (J Allergy Clin Immunol 1997) found that SCIT-treated dust-mite-monosensitized children were significantly less likely to develop new sensitizations compared to untreated controls. The PAT study's 10-year follow-up (Jacobsen et al., Allergy 2007) confirmed fewer new sensitizations in SCIT-treated children — 25% of SCIT-treated versus 45% of controls developed asthma, suggesting the same immune regulation that prevents asthma also suppresses new sensitization. This benefit — if real — would represent one of the most 'permanent' effects of SCIT, persisting long after the primary allergy symptoms have been addressed. Di Bona's systematic review notes that most positive findings come from non-randomized studies, so some uncertainty remains.